<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545073</url>
  </required_header>
  <id_info>
    <org_study_id>IOL-VTV-01</org_study_id>
    <nct_id>NCT04545073</nct_id>
  </id_info>
  <brief_title>Outcomes of a Trifocal IOL in Post-refractive Patients</brief_title>
  <acronym>TrIPLe</acronym>
  <official_title>Outcomes of a Trifocal IOL in Post-refractive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vance Thompson Vision ND</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vance Thompson Vision ND</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the prediction error of ORA vs formula for post-LASIK cataract patients when&#xD;
      PanOptix IOL was implanted. Using post-operative outcomes to determine if preoperative IOL&#xD;
      calculations, including Barrett TK, Barrett Universal II, Hill RBF, ASCRS post-refractive&#xD;
      calculator, or intraoperative aberrometry is more accurate when the two methods disagree in&#xD;
      patients who have had previous refractive surgery undergo cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be non-interventional with data being collected prospectively and&#xD;
      retrospectively between at least two surgical sites. All subjects will have previous LASIK&#xD;
      and be at least 3 months post op PanOptix implantation. The study will enroll up to 200&#xD;
      patients and a statistical database will be created.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if preoperative IOL calculations or intraoperative aberrometry is more accurate when the two methods disagree in patients who have had previous refractive surgery undergo cataract surgery.</measure>
    <time_frame>Pre-op to 9 month visit</time_frame>
    <description>Percentage of eyes within +/- .5D of target for each formula and ORA.&#xD;
Overall % of eyes that have a disagreement between the two methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative monocular visual acuity</measure>
    <time_frame>3 to 9 month visit</time_frame>
    <description>Monocular Uncorrected Distance, Intermediate, Near Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative best corrected visual acuity</measure>
    <time_frame>3 to 9 month visit</time_frame>
    <description>Manifest refraction, Best Corrected Distance Visual Acuity, Distance Corrected Intermediate, and Near Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative uncorrected visual acuity</measure>
    <time_frame>3 to 9 month visit</time_frame>
    <description>Binocular Uncorrected Distance, Intermediate, Near Visual Acuity, Best Corrected Distance Visual Acuity, Distance Corrected Intermediate, Near Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative visual acuity</measure>
    <time_frame>3 to 9 month visit</time_frame>
    <description>Percentage of eyes with Uncorrected Distance Visual Acuity of 20/20 or better, 20/25 or better, and 20/30 or better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative visual acuity</measure>
    <time_frame>3 to 9 month visit</time_frame>
    <description>Percentage of eyes with Uncorrected Corrected Intermediate Visual Acuity and Distance Corrected Intermediate Visual Acuity 20/20 or better, 20/25 or better, and 20/30 or better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative visual acuity</measure>
    <time_frame>3 to 9 month visit</time_frame>
    <description>Percentage of eyes with Uncorrected Distance Near Visual Acuity and Distance Corrected Near Visual Acuity of 20/20 or better, 20/25 or better, and 20/30 or better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's quality of vision and reported side-effects</measure>
    <time_frame>3 to 9 month visit</time_frame>
    <description>Patient satisfaction questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Refractive Errors</condition>
  <arm_group>
    <arm_group_label>Post-refractive trifocal IOL</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PanOptix</intervention_name>
    <description>Trifocal IOL with ORA in post refractive patients</description>
    <arm_group_label>Post-refractive trifocal IOL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Charts from up to 200 myopic post-refractive patients who have received PanOptix will be&#xD;
        reviewed at at least two Vance Thompson Vision sites (Fargo, ND and Sioux Falls, SD). All&#xD;
        patients will have had ORA used during the cataract surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous myopic refractive surgery&#xD;
&#xD;
          -  At least 3 months post op cataract surgery with a trifocal IOL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing or subsequent eye condition that interferes with accurate data collection&#xD;
             (retinal detachment, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Greenwood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vance Thompson Vision ND</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Thiede</last_name>
    <phone>7015665390</phone>
    <email>sarah.thiede@vancethompsonvision.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vance Thompson Vision ND</name>
      <address>
        <city>W. Fargo</city>
        <state>North Dakota</state>
        <zip>58078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Thiede</last_name>
      <phone>701-566-5390</phone>
      <email>sarah.thiede@vancethompsonvision.com</email>
    </contact>
    <contact_backup>
      <last_name>Jake Hutchison</last_name>
      <phone>701-566-5390</phone>
      <email>jake.hutchison@vancethompsonvision.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Greenwod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Risbrudt, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

